How the Hell do I Prioritize Work, Blog & Find Balance?

Both Sides of the Table

I don’t know Ezra yet but since he’s taking the time to blog (which I hugesly respect) and share thoughts I thought I’d take him up on his challenge and also spill the beans on my secrets. On blogging I blog because I love it. My other secret on blogging?

Entrepreneurshit. The Blog Post on What It’s Really Like.

Both Sides of the Table

It’s 4.50am. Sunday morning. And I couldn’t sleep. I have much on my mind since I just returned from a week on the road. 5 days. 3 cities. Late night Mexican food. Beers. Airports. Delays. I left on a Sunday. I had to miss a full day with my family, camping in the mountains.

HipGeo Launches Updated iPhone Travel Blogging App

socalTECH

The company said the redesign came after finding that users were interested in using its tools to create blog-like travel and trip journals, rather than the original, animated slideshows the tool provided. networking social blogging travel iphone hipgeo

Blogging for the Hell of It, Not Blogging to Stay Relevant

Both Sides of the Table

I used to love blogging. Blogging proved to be a great way to hone my ideas, have public conversations with people and as it turns out – build meaningful relationships through public dialog that spilled over into the real world. Somewhere along the way blogging changed. Fred Wilson said as much in his blog post today, too. I guess it’s just a reality of blogging and I accept that. I like “single take” blogging.

Notes From the JPM ’18 Vortex: Gene Therapy’s Reckoning and Lonely Cabs

Xconomy

The annual J.P. Morgan Healthcare conference in San Francisco winds down today, meaning the remaining stragglers are either presenting to half-empty rooms or headed back to colder climes.

After Paper Shakes Sector, Gene Therapy Leader Jim Wilson Talks Safety

Xconomy

Gene therapy pioneer James Wilson and University of Pennsylvania colleagues sounded an alarm Tuesday morning about the use of gene therapy to treat severe diseases like spinal muscular atrophy and Duchenne muscular dystrophy, sending a chill across the sector.

Study 25

Immunotherapy Shakeup: AstraZeneca Inks Merck Deal as Drug Combo Fails

Xconomy

Despite all the great progress made harnessing the immune system to fight cancer, there is still much work to be done to maximize its potential.

Study 39

First U.S. Gene Therapy, Approved for Vision Loss, to Cost $850,000

Xconomy

The first gene therapy approved in the United States will cost $850,000, its developer Spark Therapeutics (NASDAQ: ONCE ) announced today.

Ideas 28

FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue Type

Xconomy

For many years, doctors and researchers have known that cancers in different parts of the body can share genetic abnormalities. For the first time, the FDA has approved a drug based on those abnormalities and not on the organ in which the cancer originated.

Countering Cybersecurity Turnover: 57 Companies That Do It Best

Xconomy

What does it take to keep highly skilled cybersecurity employees? Salary and benefits are table-stakes.

Woodcock: New Approvals Show FDA is Adapting to Precision Medicine

Xconomy

The randomized controlled trial has long been held up as the gold standard for testing new drugs. But the nation’s top drug evaluator, Janet Woodcock, believes they aren’t necessary for all new experimental treatments.

Expanding Tissue and Squeezing Cells: Meet Xconomy’s Young Innovator Award Finalists

Xconomy

View the Slideshow The finalists in the Young Innovator category of the 2017 Xconomy Awards show that it’s never too early in life to start a company or invent a new technology.

Amid Gender Gap Talk, Mentor Network Emerges For Women In Health, Bio

Xconomy

It’s been more than a year since an infamous party with hired models in cocktail dresses captured the biotech community’s attention at the 2016 J.P. Morgan conference. There has been plenty of talk since about closing biotech’s notable gender gap. At this year’s J.P

Dell Med’s DeSalvo Discusses Health IT Now, and in Years to Come

Xconomy

Karen DeSalvo has experience working in the public sector, but she’s hardly what you’d call a government bureaucrat. DeSalvo, who is trained as a physician, served as the National Coordinator for Health Information Technology from 2014 to 2016 under President Barack Obama. During some of the time she headed the ONC, as the office is known, DeSalvo was also Assistant U.S. Secretary for Health , a position within the Department of Health and Human Services (HHS).

Should You Bother Targeting the Tech Blogs for Your PR Campaigns?

Both Sides of the Table

6 or 7 years ago when TechCrunch was at its peak market share (they are still strong but many more tech blogs have also popped up) there was a term for getting covered there called “the TechCrunch bounce.” that they probably read the main tech blogs.

Vinod Khosla on A.I., Health, and the Future of Working (or Not)

Xconomy

Entrepreneur-turned-venture capitalist Vinod Khosla made big headlines almost six years ago when he wrote a blog post called “Do We Need Doctors or Algorithms?”

The Painfully Poor Record of New Pain Drug Development: BIO Report

Xconomy

With the opioid epidemic showing little sign of letting up, new ways of treating chronic pain are desperately needed.

Unanimous Advice To FDA: Approve Landmark CAR-T Cancer Therapy

Xconomy

The first ever approval of a new kind of cancer immunotherapy called CAR-T is one step closer.

The Winners of the 2017 Xconomy Awards Are…

Xconomy

We are excited to announce the recipients of the first-ever Xconomy Awards.

Ideas 31

Interesting New Tech Blog for your Radar Screen

Both Sides of the Table

Over the holiday I became aware of a new tech blog that aims to have deep insights into the next generation of technology, which they call The Hypernet.

Google Launches a MOOC to Train Entry-Level IT Support Staffers

Xconomy

Big tech companies like Google are facing heat for developing disruptive technologies that can make traditional jobs obsolete. But at the same time, the tech industry is growing fast, and is eager to recruit workers outside the sector to fill entry-level jobs that often go begging, a Google executive says. Google is betting on online learning as an on-ramp to tech jobs for displaced workers and others with little exposure to information technology—even those who lack a college degree.

Cybersecurity Firm Illumio’s Alan Cohen on the Tech Backlash of 2017

Xconomy

One of the largest and most consequential data breaches in 2017 afflicted credit reporting agency Equifax, and it was hardly the only victim. Any year-end review of technology news must also include reports on Russian hacking of the 2016 election campaign, and the manipulation of social media channels to spread false and divisive political messages.

Xconomy Awards: The Finalists Are….

Xconomy

Boston Boston blog main Boston top stories Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Life Sciences xconomyawardsboston

Stratim CEO Sees Future with Costly Driverless Cars, but Low Ride Fares

Xconomy

Like many tech entrepreneurs, Sean Behr had a young business that was popular with consumers, but was also losing money. So in February of 2016, he decided to refocus his San Francisco startup on the small, but unexpectedly profitable aspect of his service that could operate in the black.

Spark CEO Marrazzo on Gene Therapy Pricing & Paving the Way for the Field

Xconomy

After decades of research and scientific ups and downs, the first U.S. gene therapy, a single, long-lasting treatment called voretigene neparvovec (Luxturna) for rare, inherited blindness, is now on the market. But the commercial challenge facing its developer, Spark Therapeutics, is daunting. Can Spark lead the way in showing that the new kinds of payment models it is experimenting with will succeed in getting the healthcare system to pay for such pricey, one-time treatments?

Novartis: CAR-T Results In One Month, Or No Charge. Why One Month?

Xconomy

Novartis said Wednesday that it would not charge for its newly approved cellular immunotherapy, tisagenlecleucel (Kymriah)—the first so-called CAR-T product to ever come to market—if it fails to help patients within a month.

The Xconomy Roadmap: Top 15 Innovation Areas to Watch (and Disrupt)

Xconomy

View the Slideshow It is a time of great transitions in the technology and business world. Key advances in areas like machine intelligence, agriculture, and healthcare seem poised to transform society—and everyday life.

Tamr’s Andy Palmer on Diversity in Tech & A.I.’s Data Challenge

Xconomy

As 2017 comes to a close, we’re surveying business and technology leaders from around our network to get their perspectives on the year in tech—and what’s next. Below are the highlights from our e-mail exchange with entrepreneur and investor Andy Palmer, the co-founder and CEO of Cambridge, MA-based Tamr , a “data unification” software company. Palmer previously co-founded Vertica Systems, now part of HP.)

Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000

Xconomy

Ahead of schedule, Novartis has received the first-ever approval of a genetically modified living cell therapy called CAR-T, which uses a cancer patient’s own immune cells as the medicine.

Bio Roundup: GOP Vote-a-Rama, Immunotherapy Setbacks, Pharma Revamps

Xconomy

Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Accelerator Corp.

Study 30

VC Confidence Holds Steady in Quarterly Survey, But Reasons Change

Xconomy

Gottlieb Reportedly On Tap to Lead FDA, and Biopharma Exhales

Xconomy

According to several news reports, the Trump administration will nominate Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences industry breathing a sigh of relief Friday afternoon.

News 34

Bio Roundup: Frazier v. Trump, Data Dumps, New York Steps & More

Xconomy

The CEO of a major U.S. pharmaceutical company was in the news this week, but for a change not because of the cost of drugs. Merck CEO Kenneth Frazier (pictured) was the first of what quickly became a line of CEOs to exit President Trump’s manufacturing council, leading to its dissolution altogether.